Published in Hum Gene Ther Methods on May 02, 2013
Gene therapy on the move. EMBO Mol Med (2013) 1.10
CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells. Exp Hematol (2015) 0.90
Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis. Mol Ther (2014) 0.85
Lentiviral vectors containing mouse Csf1r control elements direct macrophage-restricted expression in multiple species of birds and mammals. Mol Ther Methods Clin Dev (2014) 0.77
CRISPR/Cas9-generated p47(phox)-deficient cell line for Chronic Granulomatous Disease gene therapy vector development. Sci Rep (2017) 0.75
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med (2008) 15.30
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science (2000) 10.40
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med (2006) 9.68
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science (2009) 8.80
Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature (2008) 8.69
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet (2007) 7.01
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature (2010) 6.95
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (2002) 6.46
Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog (2009) 5.40
Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol (2007) 5.36
Long-term propagation of distinct hematopoietic differentiation programs in vivo. Cell Stem Cell (2007) 5.14
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med (2010) 4.76
Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood (2009) 4.06
Hematopoietic fingerprints: an expression database of stem cells and their progeny. Cell Stem Cell (2007) 4.06
The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest (2009) 3.34
An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell (2007) 3.34
Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med (2006) 3.11
Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med (2010) 3.09
Chronic granulomatous disease: the European experience. PLoS One (2009) 3.04
Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med (2010) 2.61
Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther (2009) 2.56
Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther (2008) 2.56
Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell (2007) 2.55
Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent. J Allergy Clin Immunol (2011) 2.25
Modern management of chronic granulomatous disease. Br J Haematol (2008) 2.05
Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy. Sci Transl Med (2010) 1.84
Cellular barcoding tool for clonal analysis in the hematopoietic system. Blood (2010) 1.81
Expression profiling of human immune cell subsets identifies miRNA-mRNA regulatory relationships correlated with cell type specific expression. PLoS One (2012) 1.76
Dual role of phagocytic NADPH oxidase in bacterial killing. Blood (2004) 1.56
Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther (2010) 1.34
Kinetics and mechanism of the bactericidal action of human neutrophils against Escherichia coli. Blood (1984) 1.25
Pois(s)on--it's a question of dose... Gene Ther (2004) 1.23
Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther (2009) 1.21
Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther (2010) 1.11
Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J Clin Invest (2012) 1.10
Development of a synthetic promoter for macrophage gene therapy. Hum Gene Ther (2006) 1.09
Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter. Gene Ther (2011) 1.06
Variable correction of host defense following gene transfer and bone marrow transplantation in murine X-linked chronic granulomatous disease. Blood (2001) 1.05
Physiological and tissue-specific vectors for treatment of inherited diseases. Gene Ther (2010) 0.90
A minimal c-fes cassette directs myeloid-specific expression in transgenic mice. Blood (2000) 0.88
Signed outside: a surface marker system for transgenic cytoplasmic proteins. Gene Ther (2010) 0.80
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med (2006) 9.68
Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med (2008) 4.93
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med (2010) 4.76
Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood (2009) 4.06
Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med (2008) 3.85
Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol (2009) 3.70
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med (2011) 3.63
Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet (2003) 3.44
Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood (2010) 3.23
Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol (2011) 3.05
Chronic granulomatous disease: the European experience. PLoS One (2009) 3.04
Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol (2007) 2.98
Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol (2008) 2.50
Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol (2010) 2.35
Targeted cell entry of lentiviral vectors. Mol Ther (2008) 2.34
Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) (2010) 2.33
Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) (2010) 2.26
Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent. J Allergy Clin Immunol (2011) 2.25
Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev (2006) 2.10
A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest (2003) 1.92
Bacillus Calmette Guerin triggers the IL-12/IFN-gamma axis by an IRAK-4- and NEMO-dependent, non-cognate interaction between monocytes, NK, and T lymphocytes. Eur J Immunol (2004) 1.83
Lycopene: modes of action to promote prostate health. Arch Biochem Biophys (2004) 1.65
Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen. Clin Infect Dis (2009) 1.60
From idiopathic infectious diseases to novel primary immunodeficiencies. J Allergy Clin Immunol (2005) 1.54
Correlation between recent thymic emigrants and CD31+ (PECAM-1) CD4+ T cells in normal individuals during aging and in lymphopenic children. Eur J Immunol (2007) 1.52
Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica (2006) 1.50
Sustained expansion and transgene expression of coagulation factor VIII-transduced cord blood-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol (2003) 1.50
Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice. Blood (2011) 1.48
Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood (2005) 1.48
Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol (2006) 1.46
[Breakthrough in gene therapy? Interview by Friederike Klein]. MMW Fortschr Med (2006) 1.39
Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther (2010) 1.34
CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica (2010) 1.30
Sustained persistence of transplanted proangiogenic cells contributes to neovascularization and cardiac function after ischemia. Circ Res (2008) 1.28
A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside. J Clin Immunol (2013) 1.27
DNA damage in oocytes induces a switch of the quality control factor TAp63α from dimer to tetramer. Cell (2011) 1.25
The NEMO mutation creating the most-upstream premature stop codon is hypomorphic because of a reinitiation of translation. Am J Hum Genet (2006) 1.24
Primary immunodeficiency diseases: an update. J Allergy Clin Immunol (2004) 1.23
Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells (2010) 1.23
Rho inhibition induces migration of mesenchymal stromal cells. Stem Cells (2007) 1.22
Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J Allergy Clin Immunol (2004) 1.17
Identification of severe combined immunodeficiency by T-cell receptor excision circles quantification using neonatal guthrie cards. J Pediatr (2009) 1.15
Quantification of κ-deleting recombination excision circles in Guthrie cards for the identification of early B-cell maturation defects. J Allergy Clin Immunol (2011) 1.13
Isoflurane and sevoflurane provide equally effective anaesthesia in laboratory mice. Lab Anim (2010) 1.12
Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther (2010) 1.11
Derivation and functional analysis of patient-specific induced pluripotent stem cells as an in vitro model of chronic granulomatous disease. Stem Cells (2012) 1.11
Gene therapy on the move. EMBO Mol Med (2013) 1.10
A ubiquitous chromatin opening element prevents transgene silencing in pluripotent stem cells and their differentiated progeny. Stem Cells (2013) 1.09
Implantation of personalized, biocompatible mitral annuloplasty rings: feasibility study in an animal model. Interact Cardiovasc Thorac Surg (2013) 1.09
Gene therapy for primary immunodeficiencies: Part 2. Curr Opin Immunol (2012) 1.09
Autophagy proteins stabilize pathogen-containing phagosomes for prolonged MHC II antigen processing. J Cell Biol (2013) 1.07
Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. Mol Ther (2011) 1.04
Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. J Allergy Clin Immunol (2010) 1.03
MHC class II molecules enhance Toll-like receptor mediated innate immune responses. PLoS One (2010) 1.03
Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells. Cancer Res (2007) 1.02
Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J (2004) 1.02
Assessment of postsurgical distress and pain in laboratory mice by nest complexity scoring. Lab Anim (2013) 1.01
Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy. Eur Heart J (2010) 1.01
An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol Ther (2010) 1.00
Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity. Mol Ther (2012) 0.98
SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control. Blood (2012) 0.97
Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. Pediatrics (2009) 0.97
Advances in the treatment of Chronic Granulomatous Disease by gene therapy. Curr Gene Ther (2007) 0.97
Intact indoleamine 2,3-dioxygenase activity in human chronic granulomatous disease. Clin Immunol (2010) 0.96
Burrowing behavior as an indicator of post-laparotomy pain in mice. Front Behav Neurosci (2010) 0.96
NEMO is a key component of NF-κB- and IRF-3-dependent TLR3-mediated immunity to herpes simplex virus. J Allergy Clin Immunol (2011) 0.96
Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer. Infect Immun (2008) 0.95
The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex. Blood (2002) 0.95
Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation (2005) 0.95
Clonal analysis of multipotent stromal cells derived from CD271+ bone marrow mononuclear cells: functional heterogeneity and different mechanisms of allosuppression. Haematologica (2013) 0.92
Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing. Curr Gene Ther (2015) 0.91
Therapeutic strategy in p47-phox deficient chronic granulomatous disease presenting as inflammatory bowel disease. J Allergy Clin Immunol (2010) 0.90
Factors influencing the efficacy of intra-articular steroid injections in patients with juvenile idiopathic arthritis. Eur J Pediatr (2007) 0.90
Transcatheter based electromechanical mapping guided intramyocardial transplantation and in vivo tracking of human stem cell based three dimensional microtissues in the porcine heart. Biomaterials (2013) 0.89
Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity. Blood (2010) 0.89
Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing. Mol Ther (2012) 0.88
Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells. Thromb Haemost (2004) 0.88
Characterization of 17 new cases of X-linked chronic granulomatous disease with seven novel mutations in the CYBB gene. Exp Hematol (2006) 0.87
Extracerebellar MRI-lesions in ataxia telangiectasia go along with deficiency of the GH/IGF-1 axis, markedly reduced body weight, high ataxia scores and advanced age. Cerebellum (2010) 0.87